{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:17:05Z","timestamp":1794435425393,"version":"4.9.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Although ABO-incompatible (ABOi) kidney transplantation (KT) has been performed successfully, a standard preconditioning regimen has not been established. Based on the initial antidonor ABO antibody titers, an individualized preconditioning regimen is developed, and this study explored the efficacy and safety of the regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>From September 1, 2014, to September 1, 2020, we performed 1668 consecutive living-donor KTs, including 100 ABOi and 1568 ABO-compatible (ABOc) KTs. ABOi KT recipients (KTRs) with a lower antibody titer (\u22641:8) were administered oral immunosuppressive drugs (OIs) before KT, while patients with a medium titer (1:16) received OIs plus antibody-removal therapy (plasma exchange\/double-filtration plasmapheresis), patients with a higher titer (\u22651:32) were in addition received rituximab (Rit). Competing risk analyses were conducted to estimate the cumulative incidence of infection, acute rejection (AR), graft loss, and patient death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After propensity score analyses, 100 ABOi KTRs and 200 matched ABOc KTRs were selected. There were no significant differences in graft and patient survival between the ABOi and ABOc groups\n                      <jats:italic toggle=\"yes\">(P<\/jats:italic>\n                      \u200a=\u200a0.787,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.386, respectively). After using the individualized preconditioning regimen, ABOi KTRs showed a similar cumulative incidence of AR (10.0%\n                      <jats:italic toggle=\"yes\">\u03c5s<\/jats:italic>\n                      . 10.5%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.346). Among the ABOi KTRs, the Rit-free group had a similar cumulative incidence of AR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.714) compared to that of the Rit-treated group. Multivariate competing risk analyses revealed that a Rit-free regimen reduced the risk of infection (HR: 0.31; 95% CI: 0.12\u20130.78,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.013). Notably, antibody titer rebound was more common in ABOi KTRs receiving a Rit-free preconditioning regimen (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.013) than those receiving Rit. ABOi KTRs with antibody titer rebound had a 2.72-fold risk of AR (HR: 2.72, 95% CI: 1.01\u20137.31,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.048). ABOi KTRs had similar serum creatinine and estimated glomerular filtration rate compared to those of ABOc KTRs after the first year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>An individualized preconditioning regimen can achieve comparable graft and patient survival rates in ABOi KT with ABOc KT. Rit-free preconditioning effectively prevented AR without increasing the risk of infectious events in those with lower initial titers; however, antibody titer rebound should be monitored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002138","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T20:00:25Z","timestamp":1663185625000},"page":"2303-2310","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation"],"prefix":"10.1097","volume":"135","author":[{"given":"Saifu","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiling","family":"Tan","sequence":"additional","affiliation":[{"name":"The Third Comprehensive Care Unit, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianding","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.TP.0000435703.61642.43","article-title":"Transplantation results of completely HLA-mismatched living and completely HLA-matched deceased-donor kidneys are comparable","volume":"97","author":"Laging","year":"2014","journal-title":"Transplantation"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/01.tp.0000296031.41424.f8","article-title":"Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab","volume":"84","author":"Genberg","year":"2007","journal-title":"Transplantation"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1093\/ndt\/gfq229","article-title":"Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis","volume":"25","author":"Wilpert","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20250603","first-page":"307","article-title":"ABO-incompatible kidney transplantation: long-term outcomes","author":"Tanabe","year":"2013","journal-title":"Clin Transpl"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/ajt.13502","article-title":"ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management","volume":"16","author":"Okumi","year":"2016","journal-title":"Am J Transplant"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/TP.0b013e3181726849","article-title":"ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up","volume":"85","author":"Genberg","year":"2008","journal-title":"Transplantation"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trim.2011.05.002","article-title":"Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation","volume":"25","author":"Tanabe","year":"2011","journal-title":"Transpl Immunol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1600-6143.2004.00507.x","article-title":"Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy","volume":"4","author":"Sonnenday","year":"2004","journal-title":"Am J Transplant"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/TP.0000000000000029","article-title":"Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients","volume":"98","author":"Lentine","year":"2014","journal-title":"Transplantation"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(18)32091-9","article-title":"Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis","volume":"393","author":"Scurt","year":"2019","journal-title":"Lancet"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/AOT.920224","article-title":"Individualized preconditioning for ABO-incompatible living-donor kidney transplantation: an initial report of 48 cases from China","volume":"25","author":"Wang","year":"2020","journal-title":"Ann Transplant"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcp.14876","article-title":"Tacrolimus variability score outperforms coefficient of variation in predicting clinical outcomes of living kidney transplantation","volume":"88","author":"Yin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dom.13926","article-title":"Propensity score methods in real-world epidemiology: a practical guide for first-time users","volume":"22","author":"Loke","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/TP.0000000000003285","article-title":"Competing risk analysis in renal allograft survival: a new perspective to an old problem","volume":"105","author":"El Ters","year":"2021","journal-title":"Transplantation"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2215\/CJN.10301016","article-title":"Statistical methods for cohort studies of CKD: survival analysis in the setting of competing risks","volume":"12","author":"Hsu","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tri.12234","article-title":"Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation","volume":"27","author":"Barnett","year":"2014","journal-title":"Transpl Int"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/ajt.12920","article-title":"ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone","volume":"14","author":"Masterson","year":"2014","journal-title":"Am J Transplant"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/TP.0b013e318245b2af","article-title":"Outcomes of ABO-incompatible kidney transplantation in the United States","volume":"93","author":"Montgomery","year":"2012","journal-title":"Transplantation"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/ndt\/gfr215","article-title":"Increase of infectious complications in ABO-incompatible kidney transplant recipients\u2014a single centre experience","volume":"26","author":"Habicht","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.00540118","article-title":"ABO-incompatible kidney transplant outcomes: a meta-analysis","volume":"13","author":"de Weerd","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R21-20250603","first-page":"1","article-title":"Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: advantages and disadvantages of rituximab pretreatment","author":"Okada","year":"2017","journal-title":"Clin Transplant"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","author":"Kamar","year":"2010","journal-title":"Am J Transplant"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/ndt\/gfw017","article-title":"The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation","volume":"31","author":"Lee","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/nep.13412","article-title":"Clinical significance of isoagglutinin titre with the current desensitization protocol in ABO-incompatible kidney transplantation","volume":"24","author":"Baek","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1600-6143.2010.03103.x","article-title":"ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation","volume":"10","author":"Tobian","year":"2010","journal-title":"Am J Transplant"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/tri.12482","article-title":"Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation","volume":"28","author":"Ishida","year":"2015","journal-title":"Transpl Int"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000355855","article-title":"Impact of the baseline anti-A\/B antibody titer on the clinical outcome in ABO-incompatible kidney transplantation","volume":"124","author":"Chung","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-6143.2004.00653.x","article-title":"ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab","volume":"5","author":"Tyd\u00e9n","year":"2005","journal-title":"Am J Transplant"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/trf.15672","article-title":"ABO- incompatible kidney transplantation can be successfully conducted by monitoring IgM isoagglutinin titers during desensitization","volume":"60","author":"Kim","year":"2020","journal-title":"Transfusion"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-6143.2007.02036.x","article-title":"Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation","volume":"8","author":"Setoguchi","year":"2008","journal-title":"Am J Transplant"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/TP.0000000000000556","article-title":"Incidence and outcome of C4d staining with tubulointer-stitial inflammation in blood group-incompatible kidney transplantation","volume":"99","author":"Couzi","year":"2015","journal-title":"Transplantation"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/TP.0000000000001403","article-title":"Evaluation of microvascular inflammation in ABO-incompatible kidney transplantation","volume":"101","author":"Ishihara","year":"2017","journal-title":"Transplantation"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000002487","article-title":"Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation","volume":"103","author":"Parajuli","year":"2019","journal-title":"Transplantation"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:00:17Z","timestamp":1748962817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002138","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]}}}